Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87%
Market Cap: 12.5B SEK
Have any thoughts about
Calliditas Therapeutics AB?
Write Note

Calliditas Therapeutics AB
Investor Relations

Calliditas Therapeutics AB, a biopharmaceutical company based in Sweden, has carved a niche for itself in the realm of specialty pharmaceuticals, particularly focusing on rare diseases. The company stands out with its dedication to developing novel treatments for orphan conditions that traditionally go under-addressed by larger pharmaceutical entities. Pivotal to its identity, Calliditas leverages its expertise in renal and hepatic diseases, emphasizing precision medicine aimed at improving the lives of patients with severe unmet medical conditions. Their flagship product, Nefecon, is a testament to their approach—designed to treat primary IgA nephropathy, a debilitating kidney disorder. By developing Nefecon with a patient-centric mindset, Calliditas aims to transform the treatment landscape, showcasing its commitment to innovation and regulatory expertise.

Revenue generation at Calliditas primarily revolves around the commercialization of its niche therapeutic solutions. The company operates through a well-structured business model that includes strategic partnerships, licensing agreements, and direct market entry. Profits are garnered through successfully translating their clinical research into approved drugs that address critical needs in the healthcare sector. In tandem with developing their portfolio, Calliditas maximizes opportunities within established and emerging markets, ensuring that their highly specialized medicines reach the patients who need them most. This strategic focus not only secures their financial standing but also emphasizes their pivotal role as a pivotal player in rare disease treatment. The resultant revenue stream and successful collaborations underscore Calliditas's capability to marry scientific advancement with commercial viability, ensuring sustainable growth in a competitive pharmaceutical landscape.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Ms. Renee Aguiar-Lucander
Chief Executive Officer
No Bio Available
Mr. Fredrik Johansson
Chief Financial Officer
No Bio Available
Lars Stubberud
Vice President of Technical Operations
No Bio Available
Ms. Asa Hillsten
Head of IR & Sustainability
No Bio Available
Mr. Brian Gorman
Group General Counsel
No Bio Available
Ms. Sandra Frithiof
Vice President of Human Resources
No Bio Available
Ms. Ann-Kristin Myde BSc
Head of Clinical Development & VP of Project Management
No Bio Available
Dr. Richard S. Philipson M.D.
Chief Medical Officer
No Bio Available
Ms. Teona Johnson
Head of US Marketing
No Bio Available
Mr. David Ferraro
Head of US Sales
No Bio Available

Contacts

Address
STOCKHOLM
Stockholm
Kungsbron 1
Contacts
+4684113005.0
www.calliditas.se